Moderna announced plans to reduce its workforce by 10% to align costs with declining vaccine revenues, especially amid reduced demand for COVID-19 shots and RSV vaccines. Concurrently, Moderna won a UK patent dispute affirming infringement by Pfizer and BioNTech over mRNA vaccine modifications. CEO Stéphane Bancel emphasized partnership strategies to advance its extensive pipeline, particularly for assets requiring collaborative development.